When Looking for CTRCD, Look at All Chambers

Background: Screening for cardiac injury in patients receiving cancer therapy is typically limited to the left ventricle despite the availability of information on structure and function of all 4 chambers. As cancer therapies are administered systemically, it is likely that chambers other than the left ventricle are affected. The authors hypothesized that cancer therapies affect all cardiac chambers and that similarities in temporal changes in multichamber morphology/function can be used to predict cancer therapy–related cardiac dysfunction (CTRCD). Objective: To ascertain how breast cancer treatment affects all 4 cardiac chambers, to determine if patient clusters based on similarities in changes in multichamber measures have dissimilar prognosis, and to explore ways to differentiated between these patient clusters. Design: Secondary analysis of a prospective cohort receiving treatment for human epidermal growth factor receptor 2–positive breast cancer. Methods: EMBRACE-MRI study rec more...